tl-925
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Feb 27, 2023 (NCT05745064)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07220408 | Phase 2 | Oct 23, 2025 | Telios Pharma, Inc. |
| NCT06686472 | Phase 2 | Oct 3, 2024 | Telios Pharma, Inc. |
| NCT06293820 | Phase 2 | Apr 11, 2024 | Telios Pharma, Inc. |
| NCT06225973 | Phase 2 | Feb 6, 2024 | Telios Pharma, Inc. |
| NCT06153342 | Phase 2 | Nov 30, 2023 | Telios Pharma, Inc. |
| NCT05745064 | Phase 2 | Feb 27, 2023 | Telios Pharma, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telios Pharma, Inc. | For profit | 6 | 6 | 1 | 2023 |
1 organizations
Page 1 / 1